Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 1, 2013, Pages 135-142

  Li, Chenggang ^a   Zhou, Xiaobo ^a   Sun, Yang ^a   Zhang, Erik ^a   Mancini, John D ^a   Parkhitko, Andrey ^a   Morrison, Tasha A ^a   Silverman, Edwin K ^a   Henske, Elizabeth P ^a   Yu, Jane J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Estrogen receptor antagonist; Extracellular matrix; Matrix metalloproteinase; Tuberin

Indexed keywords

COLLAGEN TYPE 4; ESTRADIOL; FULVESTRANT; GELATINASE A; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPHANGIOLEIOMYOMATOSIS; MALE; METASTASIS INHIBITION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

AIRWAY REMODELING; ANIMALS; ANTINEOPLASTIC AGENTS; COLLAGEN TYPE IV; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; EXTRACELLULAR MATRIX; FEMALE; LUNG; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, SCID; RATS; RECEPTORS, ESTRADIOL; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883196385     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0476OC     Document Type: Article

References (39)

1. Al-Saleem T, Kizilbash N, Bjornsson J, Patchefsky A, Eisenberg B, Hanks G, Greenberg R, Henske EP. Renal angiomyolipoma mimicking malignancy: a challenging problem in uro-oncology. UroOncology 2001;1:277-283.
2. Goncharova E, Goncharov D, Noonan D, Krymskaya VP. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 2004;167:1171-1182.
3. McCormack FX, Panos RJ, Trapnell BC, editors. Molecular basis of pulmonary disease: insights from rare lung disorders. New York: Human Press; 2010.
4. Taveira-Dasilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol 2010;8:9-19.
5. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000;75:591-594.
6. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80.
7. Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991;66:792-796.
8. Astrinidis A, Khare L, Carsillo T, Smolarek T, Au KS, Northrup H, Henske EP. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 2000;37:55-57.
9. Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med 2001;163:253-258.
10. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982.
11. Bittmann I, Dose TB, Muller C, Dienemann H, Vogelmeier C, Lohrs U. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol 1997;28:1420-1423.
12. Plank TL, Yeung RS, Henske EP. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998;58:4766-4770.
13. Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 2002;159:217-224.
14. Aubry MC, Myers JL, Ryu JH, Henske EP, Logginidou H, Jalal SM, Tazelaar HD. Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med 2000;162:749-752.
15. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, et al. Estrogen promotes the survival and pulmonary metastasis of tuberinnull cells. Proc Natl Acad Sci USA 2009;106:2635-2640.
16. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
17. Fukuda Y, Kawamoto M, Yamamoto A, Ishizaki M, Basset F, Masugi Y. Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis. Hum Pathol 1990;21:1252-1261.
18. Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997;28: 1071-1078.
19. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000;124: 267-275.
20. Zhe X,Yang Y, Jakkaraju S, Schuger L. Tissue inhibitor ofmetalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir CellMol Biol 2003;28:504-511.
21. Chilosi M, Pea M, Martignoni G, Brunelli M, Gobbo S, Poletti V, Bonetti F. Cathepsin-K expression in pulmonary lymphangioleiomyomatosis. Mod Pathol 2009;22:161-166.
22. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006;354:2621-2622.
23. Glassberg MK, Elliot SJ, Fritz J, Catanuto P, Potier M, Donahue R, Stetler-Stevenson W, Karl M. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. J Clin Endocrinol Metab 2008;93:1625-1633.
24. Moir LM, Ng HY, Poniris MH, Santa T, Burgess JK, Oliver BG, Krymskaya VP, Black JL. Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. Br J Pharmacol 2011;164:83-92.
25. Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis- like cells. Am J Respir Cell Mol Biol 2010;42:227-234.
26. Howell A. Faslodex (ICI 182780): an oestrogen receptor downregulator. Eur J Cancer 2000;36:S87-S88.
27. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000;89:817-825.
28. Johnston SR. Fulvestrant (AstraZeneca). Curr Opin Investig Drugs 2002;3:305-312.
29. Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995;136:4996-5003.
30. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata: establishment and characterization of tumor-derived cell lines. Am J Pathol 1995; 146:1568-1579.
31. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011;145:926-940.
32. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr., Wang JA, Kumaki F, Darling T, Moss J. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004;101:17462-17467.
33. Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseases: a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 2010;396:63-66.
34. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011;11:597-608.
35. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 2004;286:L694-L700.
36. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364:1595-1606.
37. Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP. MTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol.
38. Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, Karbowniczek M, Wu JJ, Finkel T, Kwiatkowski DJ, Yu JJ, et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/ sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci USA.
39. Chang WY, Clements D, Johnson SR. Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. Am J Physiol Lung Cell Mol Physiol 2010;299:L393-L400.